pixantrone has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soni, R; Tandon, V; Tripathi, P | 1 |
| Cheng, X; Deng, Y; Hu, L; Lai, C; Li, C; Liu, M; Liu, X; Luo, X; Qiu, Q; Song, Y; Su, Y; Zhao, Z; Zheng, H | 1 |
2 other study(ies) available for pixantrone and Lung Neoplasms
| Article | Year |
|---|---|
Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.
Topics: Animals; Cell Line, Tumor; Humans; Isoquinolines; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); Radiation-Sensitizing Agents | 2022 |
Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-octadecylamine conjugate for lung cancer treatment.
Topics: A549 Cells; Amines; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Compounding; Drug Delivery Systems; Humans; Isoquinolines; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; N-Acetylneuraminic Acid; Neutrophils; Particle Size; Polymers; Tumor Microenvironment | 2018 |